Multiple sclerosis (MS) is an inflammatory, autoimmune disease of the central nervous system (CNS). The pathogenesis of MS is driven by the adaptive immune system (IS) and particularly by autoreactive, myelin-specific, CD4+ T cells, which are activated in the periphery and re-activated within the CNS. There they coopt effector cells to generate the inflammatory response which ultimately leads to demyelination and axonal loss. Similarly to what happens in a NeoImpressionist painting, however, an apparent simplicity of the whole picture gives way, when looking closer, to a much more composite reality, where many different components of the IS contribute to generating the aberrant autoimmune response characterizing MS. They include other members of the adaptive IS (and particularly B cells and T regulatory cells); as well as cells belonging to the more phylogenetically ancient innate IS.
Natural killer (NK) cells are innate lymphocytes. Classically recognized as effector cells with antitumoral and anti-viral activity, their killing activity is the result of a balance between stimuli triggering their activating receptors and recognition of self-molecules by their inhibitory receptors. 1 However, far from being mere effectors, NK cells interact with both innate and adaptive immune cells, and thus, they contribute to the fate of immune responses. Until a few years ago, the role of NK cells in the context of MS pathogenesis has been debated. In the last decade scientific discoveries leading to better understanding of the multiple functions of NK cells and characterization of subsets of human NK cells with different features, as well as observations from therapeutic interventions, led to recognition of a beneficial role of NK cells, and particularly of one of their subsets, the CD56 bright NK cells, in MS.
CD56 bright NK cells are a small subset (5%-10%) of circulating NK cells, but they are the majority of NK cells in lymph nodes and other organs, and may be the most abundant NK cells in human body. They have regarded for many years as "immunoregulatory" due to higher production of cytokines compared to the more abundant CD56 dim NK cells and lower cytotoxicity toward target cells. 2 We and others have shown that in healthy subjects, human CD56 bright NK cells suppress the proliferation of autologous activated T cells 3, 4 through direct cytotoxicity toward the T cells themselves. 5 Second, it is notable that a number of effective treatments for MS enhances the number of CD56 bright NK cells, including interferon-beta, 11 alemtuzumab, 12 autologous hematopoietic stem cell transplantation (AHSCT), 9 and daclizumab. 13 The latter treatment was an anti-CD25 monoclonal antibody with pleiotropic effects on the IS; among such effects, the increase of CD56 bright NK cells was directly related to decreased disease activity and accompanied with enhanced cytotoxicity toward CD4+ T cells. 6, 13 This was, to our knowledge, the first drug in MS whose mechanism of action appeared to rely mainly on the enhancement of a regulatory immune population. Unfortunately, post-marketing experience revealed some cases of severe brain inflammation with eosinophil infiltrates (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)) and the drug was consequently withdrawn from the market. 14 To date, it seems that development of DRESS was not correlated to the effect of the drug on NK cells. More recently, Darlington et al. reported that the enhancement of NK cells after AHSCT is associated with an inhibition of pathogenic T helper 17 (Th17) responses in MS. The same study showed that NK cells kill Th17 cells through engagement of the natural killer group 2 member D (NKG2D) receptor in healthy donors. 9 Taken together, this study and the preciously cited ones suggest the hypothesis that the enhancement of CD56 bright NK cells may represent a mechanism of action and/or a biomarker of efficacy of some treatments in MS.
Finally, although the lack on expression of CD56 marker in mouse NK cells does not allow to easily translate preclinical observations to the human system, most evidence from animal studies reinforces the possibility of a beneficial role of NK cells in CNS autoimmunity. In mouse, NK cells have been shown to control Th17 responses within the CNS 10 and to mediate improvement of the clinical course of experimental autoimmune encephalomyelitis (EAE) through killing of T cells upon blockade of the function of their inhibitory receptor natural killer group 2 member A (NKG2A). 15 Interactions between NK cells and neural stem cells in the brain have a beneficial role in the early phases of EAE, but not in later stages. 16 In summary, there is scientific evidence that NK cells, and particularly their CD56 bright subset, have an immunoregulatory role that is important to maintain homeostatic immune responses in health and that is compromised in MS, due to resistance of T cells from NK cell-mediated killing. Further studies are needed to dissect the mechanisms of NK cell-T cell interactions, particularly within the lymphoid tissue, in health and MS. Restoring the immunoregulatory function of NK cells in MS is associated with decreased inflammatory responses and with amelioration of MS disease state.
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